The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-01 and is reviewed periodically as new material appears.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
=== Calculating Frequency & Probability === A database storing the sequence alignments of the most conserved regions of protein families. These alignments are used to derive the BLOSUM matrices. Only the sequences with a percentage of identity lower than the threshold are used. By using the block, counting the pairs of amino acids in each column of the multiple alignment.
== Etymology == The name "erythritol" derives from the Greek word for the color red (erythros or ἐρυθρός). The name is adapted from a closely related compound, erythrin, which turns red upon oxidation. Despite its name, erythritol is almost always found in the form of white crystals or powder, and chemical reactions do not turn it red.
== External links == "Real-world Evidence from a Narrow Therapeutic Index Product (Levothyroxine) Reflects the Therapeutic Equivalence of Generic Drug Products". U.S. Food and Drug Administration (FDA). 19 November 2020. Archived from the original on 2 October 2020. Levothyroxine pronunciation guide – audio, phonetic spelling, and syllable breakdown
Sources: en.wikipedia.org
one-step affinity purification Protein:protein interaction studies Colony blot, dot blot, Western blot and ELISA Screening for positive expression clones Immunocytochemistry and Immunohistochemistry Protein localization and targeting studies Because the Strep-tag is capable of isolating protein complexes, strategies for the study of protein-protein interactions can also be conducted. Another option is the immobilization of Strep-tag proteins with a specific high affinity antibody on microplates or biochips. Strep-Tag/StrepTactin system is also used in single-molecule optical tweezers and atomic force microscope experiments, showing high mechanical stability comparable to the strongest non-covalent linkages currently available.
A bulk material should have constant physical properties regardless of its size, but at the nano-scale this is often not the case. Size-dependent properties are observed such as quantum confinement in semiconductor particles, surface plasmon resonance in some metal particles, and superparamagnetism in magnetic materials. Nanoparticles exhibit a number of special properties relative to bulk material. For example, the bending of bulk copper (wire, ribbon, etc.) occurs with movement of copper atoms/clusters at about the 50 nm scale. Copper nanoparticles smaller than 50 nm are considered super hard materials that do not exhibit the same malleability and ductility as bulk copper. The change in properties is not always desirable. Ferroelectric materials smaller than 10 nm can switch their polarization direction using room temperature thermal energy, thus making them useless for memory storage. Suspensions of nanoparticles are possible because the interaction of the particle surface with the solvent is strong enough to overcome differences in density, which usually result in a material either sinking or floating in a liquid. Nanoparticles often have unexpected visual properties because they are small enough to confine their electrons and produce quantum effects. For example, gold nanoparticles appear deep red to black in solution. The often very high surface area to volume ratio of nanoparticles provides a tremendous driving force for diffusion, especially at elevated temperatures. Sintering is possible at lower temperatures and over shorter durations than for larger particles.
Missions played a variety of roles in the postwar world: the mission in San Francisco assisted participants in the meeting that established the United Nations, the mission in Europe acquired European publications for the Library of Congress and other American libraries, and the mission in Japan aided in the creation of the National Diet Library.
Sources: en.wikipedia.org
== Classification of fuzzy complexes == Structural ambiguity in protein complexes covers a wide spectrum. In a polymorphic complex, the protein adopts two or more different conformations upon binding to the same partner, and these conformations can be resolved. Clamp, flanking and random complexes are dynamic, where ambiguous conformations interchange with each other and cannot be resolved. Interactions in fuzzy complexes are usually mediated by short motifs. Flanking regions are tolerant to sequence changes as long as the amino acid composition is maintained, for example in case of linker histone C-terminal domains and H4 histone N-terminal domains.
However, in the 2025 study, time to maximal effects was about 2.5 hours orally and about 1.2 hours intravenously. In an earlier 2016 study, intravenous LSD effects similarly peaked after about 1.7 hours. For comparison, intravenous dimethyltryptamine (DMT) given as a bolus has been found to produce maximal effects after about 2 minutes and intravenous psilocybin given over 60 seconds produces peak effects after about 4 minutes. Doses of LSD are said to be similar by oral and injectable routes, with the exception of intrathecal injection, in which the dose is reduced to about one-third of usual. The plasma protein binding of LSD in humans is unknown, but it is 65 to 90% bound to plasma proteins in guinea pigs.
Male - 50.7% Female - 49.3% Native American/Alaskan - 0.1% Asian/Pacific islander - 0.9% Black - 0.3% Hispanic - 96.1% White - 2.4% Multiracial - 0.2% Additionally, 86.3% of the students were eligible for free or reduced lunch.
=== Role of MMPs in disease === When MMPs are dysregulated, they can make diseases become more aggressive and worsen them instead of curing them. For instance, elevated levels of MMP-1 releases growth factors that enhance cancer metastasis, and in diabetic foot ulcers it slows healing by over-degrading tissues. MMP-8 levels rise in asthma, and in diabetes, it increases the chronic inflammation. MMP-13 drives joint damage in osteoarthritis, while MMP-2 and MMP-9 levels soar in colorectal cancer and heart diseases, carrying out abnormal changes in vessel walls and causing fibrosis. MMP-3 aids rheumatoid arthritis and spine issues, MMP-10 affects bone growth, MMP-7 increases in artery-clogging atherosclerosis, and MMP-12 cause immune cells to overreact, causing severe inflammation. Basically, unchecked MMP activity turns helpful tools into troublemakers.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.